StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.41−0.07 (-14.34%)

Close on Nov 18, 2026Market cap $63.33MP/E –Yield –

Coherus Oncology revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Coherus Oncology's revenue for the twelve months ending Jun 30, 2026 was $50.94M, up 61.0% year over year. For fiscal 2025 it was $42.17M, up 59.8% from the year before. Over ten years it grew 3.5% a year on average. The highest annual figure on record is $475.82M in fiscal 2020.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$42.17M+59.8%
FY2024Dec 31, 2024$26.39M-89.7%
FY2023Dec 31, 2023$257.24M+21.9%
FY2022Dec 31, 2022$211.04M-35.4%
FY2021Dec 31, 2021$326.55M-31.4%
FY2020Dec 31, 2020$475.82M+33.6%
FY2019Dec 31, 2019$356.07M–
FY2018Dec 31, 2018$0-100.0%
FY2017Dec 31, 2017$1.56M-99.2%
FY2016Dec 31, 2016$190.11M+532.8%
FY2015Dec 31, 2015$30.04M-3.4%
FY2014Dec 31, 2014$31.11M+1030.7%
FY2013Dec 31, 2013$2.75M+44.9%
FY2012Dec 31, 2012$1.90M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.31M+39.5%
Q1 FY2026Mar 31, 2026$12.31M+62.0%
Q4 FY2025Dec 31, 2025$12.75M+64.9%
Q3 FY2025Sep 30, 2025$11.57M+91.2%
Q2 FY2025Jun 30, 2025$10.25M-0.4%
Q1 FY2025Mar 31, 2025$7.60M+229.2%
Q4 FY2024Dec 31, 2024$7.73M-91.6%
Q3 FY2024Sep 30, 2024$6.05M-91.9%
Q2 FY2024Jun 30, 2024$10.30M-82.5%
Q1 FY2024Mar 31, 2024$2.31M-92.9%
Q4 FY2023Dec 31, 2023$91.52M+101.8%
Q3 FY2023Sep 30, 2023$74.57M+64.2%
Q2 FY2023Jun 30, 2023$58.72M-2.4%
Q1 FY2023Mar 31, 2023$32.44M-46.0%
Q4 FY2022Dec 31, 2022$45.35M-38.2%
Q3 FY2022Sep 30, 2022$45.42M-44.9%
Q2 FY2022Jun 30, 2022$60.15M-31.4%
Q1 FY2022Mar 31, 2022$60.12M-27.6%
Q4 FY2021Dec 31, 2021$73.37M-33.6%
Q3 FY2021Sep 30, 2021$82.50M-27.3%
Q2 FY2021Jun 30, 2021$87.64M-35.4%
Q1 FY2021Mar 31, 2021$83.03M-28.5%
Q4 FY2020Dec 31, 2020$110.42M-10.8%
Q3 FY2020Sep 30, 2020$113.55M+1.7%
Q2 FY2020Jun 30, 2020$135.67M+62.6%
Q1 FY2020Mar 31, 2020$116.18M+213.2%
Q4 FY2019Dec 31, 2019$123.86M–
Q3 FY2019Sep 30, 2019$111.68M–
Q2 FY2019Jun 30, 2019$83.43M–
Q1 FY2019Mar 31, 2019$37.10M–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0-100.0%
Q1 FY2018Mar 31, 2018$0-100.0%
Q4 FY2017Dec 31, 2017$0-100.0%
Q3 FY2017Sep 30, 2017$0-100.0%
Q2 FY2017Jun 30, 2017$1.40M–
Q1 FY2017Mar 31, 2017$161.00K–
Q4 FY2016Dec 31, 2016$844.00K–
Q3 FY2016Sep 30, 2016$162.84M–

More Coherus Oncology figures

See a number that looks wrong?